According to a news source, the Indian Drugs Manufacturing Association is gearing up to challenge action taken by the country’s drug controller to prevent the sale of medicines under brand names as part of an effort to accelerate sales of less-expensive generics. The association’s secretary general reportedly said, “Our legal experts are studying the matter. We don’t think the government has jurisdiction over the branding of drugs. We will also be taking a presentation to the government, asking it to consult the stakeholders on such a matter.” The government’s proposal would evidently require all drug makers applying for licenses to manufacture or market fixed-dose combination drugs to submit the generic name for the product and not the brand names. See Pharmalot.com, October 19, 2012.